Psychiatry Center of Excellence

Supporting patients living with a rare or complex psychiatric condition

Orsini’s Psychiatry Center of Excellence launched in 2016 with our first program for schizophrenia. Today we support multiple psychiatry programs across several rare and complex conditions. Our dedicated Therapy Care Teams work with the physician’s office and insurance on a patient’s behalf so that our patients and their family have more time to focus on their treatment and quality of life. We are here to listen, provide counseling on treatment, including side-effect management, and assist with sourcing third-party financial assistance.

Explore Our Psychiatric Therapies

Benefits

Improving the Patient Experience, Every Time

Dedicated Care Team

Receive personalized support from a dedicated Therapy Care Team, including a primary pharmacy contact, clinical education, side-effects management, and scheduled refill calls.

Patient-Centered Care

Experience compassionate care that prioritizes patients and their families. Our team supports patients of all ages, from infants to the elderly, extending care to the entire care team.

Insurance Coverage

Secure treatment coverage with assistance navigating payor and plan requirements. Our team proactively works with prescribers to obtain prior authorization and support appeals.

Free Care Overnight Shipping

Ensure medication and essential medical supplies arrive when and where patients need them through coordination across prescribers, patients, and care teams to arrange free overnight shipping.

Financial Assistance

Minimize financial exposure through financial assistance programs. We successfully identify and assist in enrolling patients into manufacturer co-pay and foundation support programs.

24/7/365 Access to a Pharmacist

Gain continuous access to a pharmacist, 24/7/365, ensuring ongoing care and clinical support for patients and prescribers to achieve better outcomes.

Support

Psychiatry Conditions Supported

Explore the psychiatry conditions and therapies Orsini supports below.

About Huntington’s Disease Chorea

Huntington’s disease chorea is a progressive neurodegenerative disorder characterized by involuntary, jerky movements known as chorea. This hereditary condition results from a mutation in the HTT gene, leading to the degeneration of nerve cells in the brain. Chorea involves random, uncontrollable muscle contractions, affecting coordination and voluntary movements. As Huntington’s disease advances, it causes cognitive decline, emotional disturbances, and impaired motor skills. The relentless nature of chorea significantly impacts an individual’s quality of life, requiring comprehensive support and care.

Providers can refer patients to Orsini by filling out and submitting our Movement Disorders Enrollment Form.

Huntington’s Disease Chorea Therapies Supported

Full Name	Austedo® (deutetrabenazine)
Drug	Austedo
Manufacturer	Teva Neuroscience, Inc.
Route of Administration	Oral
Site of Care	Home
Approved Indication	Indicated in adults for the treatment of Chorea associated with Huntington’s disease and tardive dyskinesia
Disease	Tardive Dyskinesia (TD); Huntington’s Disease Chorea
Therapeutic Area	Psychiatry, Neurology
Enrollment Form Link	Enrollment Form
Phone Number	800-691-0718
Fax Number	877-819-2424
Product Website	austedohcp.com

Full Name	Austedo® XR (deutetrabenazine)
Drug	Austedo XR Extended Release
Manufacturer	Teva Neuroscience, Inc.
Route of Administration	Oral
Site of Care	Home
Approved Indication	Indicated in adults for the treatment of Chorea associated with Huntington’s disease and tardive dyskinesia
Disease	Tardive Dyskinesia (TD); Huntington’s Disease Chorea
Therapeutic Area	Psychiatry, Neurology
Enrollment Form Link	Enrollment Form
Phone Number	800-691-0718
Fax Number	877-819-2424
Product Website	www.austedohcp.com

Full Name	Ingrezza® (valbenazine)
Drug	Ingrezza
Manufacturer	Neurocrine Biosciences
Route of Administration	Oral
Site of Care	Home
Approved Indication	The treatment of adults with tardive dyskinesia or chorea associated with Huntington’s disease
Disease	Tardive Dyskinesia (TD); Huntington’s Disease Chorea
Therapeutic Area	Psychiatry, Neurology
Enrollment Form Link	Enrollment Form
Phone Number	800-279-1676
Fax Number	877-868-1681
Product Website	ingrezzahcp.com

About Tardive Dyskinesia (TD)

Tardive dyskinesia is a neurological movement disorder typically characterized by repetitive involuntary movements of the jaw, lips, and tongue, and some individuals experience involuntary rapid jerking movements or slow, writhing movements in the arms and legs. The condition is a result of long-term use of certain types of neuroleptics, such as antipsychotics or major tranquilizers.

Providers can refer patients to Orsini by filling out and submitting our Movement Disorders Enrollment Form.

TD Therapies Supported

Full Name	Austedo® (deutetrabenazine)
Drug	Austedo
Manufacturer	Teva Neuroscience, Inc.
Route of Administration	Oral
Site of Care	Home
Approved Indication	Indicated in adults for the treatment of Chorea associated with Huntington’s disease and tardive dyskinesia
Disease	Tardive Dyskinesia (TD); Huntington’s Disease Chorea
Therapeutic Area	Psychiatry, Neurology
Enrollment Form Link	Enrollment Form
Phone Number	800-691-0718
Fax Number	877-819-2424
Product Website	austedohcp.com

Full Name	Austedo® XR (deutetrabenazine)
Drug	Austedo XR Extended Release
Manufacturer	Teva Neuroscience, Inc.
Route of Administration	Oral
Site of Care	Home
Approved Indication	Indicated in adults for the treatment of Chorea associated with Huntington’s disease and tardive dyskinesia
Disease	Tardive Dyskinesia (TD); Huntington’s Disease Chorea
Therapeutic Area	Psychiatry, Neurology
Enrollment Form Link	Enrollment Form
Phone Number	800-691-0718
Fax Number	877-819-2424
Product Website	www.austedohcp.com

Full Name	Ingrezza® (valbenazine)
Drug	Ingrezza
Manufacturer	Neurocrine Biosciences
Route of Administration	Oral
Site of Care	Home
Approved Indication	The treatment of adults with tardive dyskinesia or chorea associated with Huntington’s disease
Disease	Tardive Dyskinesia (TD); Huntington’s Disease Chorea
Therapeutic Area	Psychiatry, Neurology
Enrollment Form Link	Enrollment Form
Phone Number	800-279-1676
Fax Number	877-868-1681
Product Website	ingrezzahcp.com

Patient Advocacy Partners

The Alex Rezcalla Foundation advances the development of therapies for individuals with Duchenne muscular dystrophy (DMD) through advocacy and research funding. It raises awareness of the DMD experience by hosting events, engaging the public, and building networks of support.

Learn more at alexrezkallafoundation.org

The Amyloidosis Research improves the lives of patients with amyloidosis and accelerates cutting edge research through collaborative, groundbreaking initiatives. ARC provides support, information, and resources to patients and caregivers, empowering them to access the best care possible.

Learn more at aci.org

Cure SMA is dedicated to finding treatments and a cure for spinal muscular atrophy (SMA) by funding research and supporting families. Since 1984, Cure SMA has grown to be the largest U.S.-based network of individuals, families, clinicians, and research scientists working together to advance SMA research, support individuals and families impacted by SMA, and educate public and professional communities about SMA.

Learn more at www.curesma.org

The US Hereditary Angioedema Association (HAEA) is a 501 (c)(3) non-profit advocacy and research organization serving people living with the rare genetic condition, Hereditary Angioedema (HAE), and their families. Founded and staffed by people with HAE and caregivers, the US HAEA is committed to actively engaging our community in a wide variety of grassroots activities that promote HAE education and awareness.

Learn more at haea.org

The HypoPARAthyroidism Association is a non-profit patient association working to improve the lives of people impacted by hypoPARAthyroidism through education, support, research, and advocacy. They raise awareness of hypoPARAthyroidism and bring change to the lives of those affected.

Learn more at hypopara.org

Jett Foundation empowers people and families impacted by Duchenne muscular dystrophy through the development of transformative programming, educational opportunities, and ongoing support for every stage of a Duchenne journey.

Learn more at jettfoundation.org

Muscular Dystrophy Association (MDA) is the #1 voluntary health organization in the United States for people living with muscular dystrophy, ALS, and over 300 other neuromuscular conditions. For 75 years, MDA has led the way in accelerating research, advancing care, and advocating support and inclusion of families living with neuromuscular disease.

Learn more at mda.org

The National MPS Society is committed to making a difference in the lives of MPS families through support, research, education, and advocacy. Families from around the world gain a better understanding of these rare genetically determined diseases through the Society’s assistance in linking them with healthcare professionals, researchers, and, perhaps most importantly, each other.

Learn more at mpssociety.org

The National Niemann-Pick Disease Foundation, Inc. (NNPDF) is a non-profit, patient advocacy and family support organization dedicated to supporting and empowering patients and families affected by Niemann-Pick disease, through education, collaboration and research. Founded in 1993, NNPDF serves families throughout the nation at all stages of their Niemann-Pick journey.

Learn more at nnpdf.org

The National PKU Alliance (NPKUA) works to improves the lives of individuals with PKU, pursue a cure by expanding research, and provide education and support to individuals living with PKU and their caregivers. Since its inception in 2008, NPKUA has supported numerous successful fundraising events, conferences, and internal support programs and has remained steadfast in its support of research endeavors.

Learn more at npkua.org

Parent Project Muscular Dystrophy (PPMD) is the largest nonprofit organization in the United States focused entirely on Duchenne muscular dystrophy. They take a comprehensive approach in the fight against Duchenne—funding research, raising awareness, promoting advocacy, connecting the community, and broadening treatment options.

Learn more at parentprojectmd.org

The Pompe Alliance is a Public Services Organization dedicated to the ideas of support, empowerment, and progress. It seeks to provide supportive services and information to patients, caregivers, medical professionals, and community stakeholders through a number of initiatives: financial assistance, advocacy, education, mentoring, and research recruitment

Learn more at pompealliance.com

The mission of the Pulmonary Fibrosis Foundation is to accelerate the development of new treatments and ultimately a cure for pulmonary fibrosis. Until this goal is achieved, the PFF is committed to advancing improved care of patients with PF and providing unequaled support and education resources for patients, caregivers, family members, and health care providers.

Learn more at pulmonaryfibrosis.org

The United Pompe Foundation was formed to assist patients and/or their families with medical costs and other expenses that these patents and families face and may not be able to cover, or fully cover, through their insurance.

Learn more at unitedpompe.com